HERON THERAPEUTICS, INC. /DE/ (HRTX) Return on equity 2017–2025
HERON THERAPEUTICS, INC. /DE/ (HRTX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-140.9%FY2025 · since FY2017: -150.6% → -140.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -140.9% | — |
| FY2022 | -1341.2% | -1056.7 pp |
| FY2021 | -284.5% | -188.4 pp |
| FY2020 | -96.1% | -45.4 pp |
| FY2019 | -50.7% | -2.4 pp |
| FY2018 | -48.3% | +102.3 pp |
| FY2017 | -150.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More HRTX financial trends
HRTX RevenueHRTX Net incomeHRTX Net marginHRTX Gross profitHRTX Gross marginHRTX Operating incomeHRTX Operating marginHRTX Operating cash flowHRTX Free cash flowHRTX Capital expendituresHRTX Stock buybacksHRTX Dividends paidHRTX Total assetsHRTX Total liabilitiesHRTX Shareholders’ equityHRTX overview →